#biopharmaceuticals

Gyre Therapeutics has signed an acquisition agreement to make consolidated subsidiary Cullgen Inc. a wholly-owned subsidiary for approximately USD 300 million (approx. JPY 47 billion), with completion planned for early Q2 2026.

Nexera Pharma Inc. received $1.8 million (approximately JPY 281 million) as a milestone payment from Centessa for the development drug targeting neuropsychiatric disorders, scheduled to be recorded as revenue in the first quarter of the fiscal year ending December 2026.

Nexera Pharma has received a $3.6 million (approximately ¥565 million) milestone from Centessa and plans to record it as revenue in the fourth quarter of the fiscal year ending December 2025.